Details for New Drug Application (NDA): 205613
✉ Email this page to a colleague
The generic ingredient in UCERIS is budesonide. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 205613
Tradename: | UCERIS |
Applicant: | Salix |
Ingredient: | budesonide |
Patents: | 0 |
Pharmacology for NDA: 205613
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 205613
Suppliers and Packaging for NDA: 205613
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613 | NDA | Salix Pharmaceuticals, Inc. | 65649-651 | 65649-651-03 | 2 CANISTER in 1 CARTON (65649-651-03) / 1 AEROSOL, FOAM in 1 CANISTER (65649-651-02) |
UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613 | NDA | Oceanside Pharmaceuticals | 68682-658 | 68682-658-03 | 2 CANISTER in 1 CARTON (68682-658-03) / 1 AEROSOL, FOAM in 1 CANISTER (68682-658-02) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, FOAM;RECTAL | Strength | 2MG/ACTUATION | ||||
Approval Date: | Oct 7, 2014 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 205613
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Salix | UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613-001 | Oct 7, 2014 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription